Sodium oxybate once-nightly - Jazz Pharmaceuticals plc
Alternative Names: JZP-324Latest Information Update: 26 Feb 2024
At a glance
- Originator Jazz Pharmaceuticals plc
- Class Butyric acids; Hydroxybutyrates; Sleep disorder therapies; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Narcolepsy
Most Recent Events
- 26 Feb 2024 Sodium oxybate is still in phase I trial for Narcolepsy (In volunteers) in Ireland (PO) (Jazz Pharmaceuticals plc Pipeline, February 2024)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers) in Ireland (PO)
- 04 Sep 2020 Phase-I clinical trials in Narcolepsy (In volunteers) in Ireland (PO) before September 2020 (Jazz Pharmaceuticals pipeline, September 2020)